Skip to main content
logo
Vaxcell-Bio Therapeutics Co., Ltd. (KOSDAQ:323990)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,000.00
+275.00 (7.38%)
Nov 2, 2026, 3:30 PM KST

Vaxcell-Bio Therapeutics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
1,8991,89913.72---
Revenue Growth
13737.28%13737.28%----
Gross Profit
361.57361.573.28-16.43-19.37-5.39
Operating Income
-15,081-15,081-11,507-8,213-5,904-4,255
Net Income
-10,624-10,624-10,274-6,825-4,763-3,984
Earnings Per Share
-463.00-463.00-524.00-448.34-315.00-585.00
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Investments
36,05536,05550,04620,39227,30918,903
Total Debt
2,2682,268361.23105.24220.44339.11
Net Cash (Debt)
33,78733,78749,68520,28727,08818,563
Net Cash Growth
-32.00%-32.00%144.91%-25.11%45.92%143.91%
Net Cash Per Share
1472.501472.502534.041332.651791.572725.80

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Operating Cash Flow
-10,699-10,699-9,423-6,045-4,662-3,303
Capital Expenditures
-2,125-2,125-165.8-167.38-2,124-26.91
Free Cash Flow
-12,824-12,824-9,589-6,212-6,785-3,330
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Gross Margin
19.04%19.04%23.90%---
Operating Margin
-794.20%-794.20%-83851.26%---
Pretax Margin
-559.45%-559.45%-74865.84%---
Profit Margin
-559.45%-559.45%-74865.84%---
FCF Margin
-675.31%-675.31%-69872.25%---

Valuation
Chart
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingNov '26 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
PS Ratio
-126.2937614.61---